<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00796224</url>
  </required_header>
  <id_info>
    <org_study_id>A0661190</org_study_id>
    <nct_id>NCT00796224</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics Of Azithromycin Immediate Release And Extended Release Formulation In Kids With Acute Otitis Media</brief_title>
  <official_title>A Open Label, Randomized, Single Dose, Parallel Arm Study To Determine Pharmacokinetics Of Azithromycin Following Oral Administration Of Immediate-Release Or Extended-Release Formulation In Pediatric Subjects With Acute Otitis Media</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to determine the pharmacokinetics (PK), safety and clinical
      response following a single dose of either 30 mg/kg IR (Immediate Release) or 60 mg/kg ER
      (Extended Release) formulation in pediatric subjects 6 months to 6 years of age inclusive.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Curve From Time Zero to 72 Hours (AUC72Hours)</measure>
    <time_frame>Predose/0 to 72 Hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUC Inf)</measure>
    <time_frame>Predose/0, 1, 2, 3, 4, 8, 24, 48, 72 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of Azithromycin</measure>
    <time_frame>Predose/0, 1, 2, 3, 4, 8, 24, 48, 72 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration (Tmax) and Plasma Decay Half Life (t1/2) of Azithromycin</measure>
    <time_frame>Predose/0, 1, 2, 3, 4, 8, 24, 48, 72 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Concentrations of Azithromycin ER (Test) and Azithromycin IR (Reference)</measure>
    <time_frame>1,2,3,4,8,24,48,72 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With a Clinical Response</measure>
    <time_frame>Days 7,8,9 or 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events (AEs) and Serious AEs (SAEs)</measure>
    <time_frame>Baseline up to 28 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Acute Otitis Media</condition>
  <arm_group>
    <arm_group_label>1.</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>60 mg/kg azithromycin ER (Extended Release)arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2.</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>30 mg/kg azithromycin IR (Immediate Release) arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>60 mg/kg azithromycin ER</intervention_name>
    <description>subjects taken 60 mg/kg azithromycin ER</description>
    <arm_group_label>1.</arm_group_label>
    <other_name>Zithromax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>30 mg/kg azithromycin IR</intervention_name>
    <description>subjects taken 30 mg/kg azithromycin IR (Immediate Release)</description>
    <arm_group_label>2.</arm_group_label>
    <other_name>Zithromax</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects age 6 months to &lt; 12 years.

          -  Have clinical signs/symptoms of acute otitis media in at least one ear.

          -  Parent(s)/legal guardian(s) provide written informed consent.

        Exclusion Criteria:

          -  Clinical significant other disease.

          -  Recent use of investigational drugs, prescription or nonprescription drugs.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>11 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>San Jose</city>
        <zip>0000</zip>
        <country>Costa Rica</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>San Jose</city>
        <country>Costa Rica</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Costa Rica</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A0661190&amp;StudyName=Pharmacokinetics%20Of%20Azithromycin%20Immediate%20Release%20And%20Extended%20Release%20Formulation%20In%20Kids%20With%20Acute%20Otitis%20Media</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>February 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 18, 2008</study_first_submitted>
  <study_first_submitted_qc>November 20, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 24, 2008</study_first_posted>
  <results_first_submitted>December 15, 2009</results_first_submitted>
  <results_first_submitted_qc>December 16, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 25, 2010</results_first_posted>
  <last_update_submitted>February 1, 2010</last_update_submitted>
  <last_update_submitted_qc>February 1, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 18, 2010</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc.</organization>
  </responsible_party>
  <keyword>azithromycin, pharmacokinetics, pediatrics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Otitis</mesh_term>
    <mesh_term>Otitis Media</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azithromycin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>60 mg/kg Azithromycin Extended-release (ER)</title>
          <description>Subjects received 60 mg/kg Azithromycin ER single oral dose on Day 1.</description>
        </group>
        <group group_id="P2">
          <title>30 mg/kg Azithromycin Immediate-release (IR)</title>
          <description>Subjects received 30 mg/kg Azithromycin IR single oral dose on Day 1.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>60 mg/kg Azithromycin ER</title>
          <description>Subjects received 60 mg/kg Azithromycin ER single oral dose on Day 1.</description>
        </group>
        <group group_id="B2">
          <title>30 mg/kg Azithromycin IR</title>
          <description>Subjects received 30 mg/kg Azithromycin IR single oral dose on Day 1.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
            <count group_id="B2" value="19"/>
            <count group_id="B3" value="38"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>1 month to &lt;2 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 years to &lt;12 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Curve From Time Zero to 72 Hours (AUC72Hours)</title>
        <description>AUC72 = Area under the plasma concentration versus time curve from time zero (pre-dose) to 72 hours.</description>
        <time_frame>Predose/0 to 72 Hours</time_frame>
        <population>All subjects randomized and treated who had at least 1 of the pharmacokinetic parameters of primary interest.</population>
        <group_list>
          <group group_id="O1">
            <title>60 mg/kg Azithromycin ER</title>
          </group>
          <group group_id="O2">
            <title>30 mg/kg Azithromycin IR</title>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve From Time Zero to 72 Hours (AUC72Hours)</title>
          <description>AUC72 = Area under the plasma concentration versus time curve from time zero (pre-dose) to 72 hours.</description>
          <population>All subjects randomized and treated who had at least 1 of the pharmacokinetic parameters of primary interest.</population>
          <units>ng*hr/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12173.023" spread="6305.0325"/>
                    <measurement group_id="O2" value="7950.949" spread="4759.3010"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Test (60 mg/kg Azithromycin ER)/ Reference (30 mg/kg Azithromycin IR)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of Geometric Means</param_type>
            <param_value>157.98</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>98.87</ci_lower_limit>
            <ci_upper_limit>252.44</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUC Inf)</title>
        <description>AUCinf = AUClast + (Clast* divided by kel), where AUClast is calculated by Linear-Log trapezoidal method, Clast* is the predicted serum concentration at the last quantifiable time point estimated from the log-linear regression analysis and kel is the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.</description>
        <time_frame>Predose/0, 1, 2, 3, 4, 8, 24, 48, 72 hours post-dose</time_frame>
        <population>All subjects randomized and treated who had at least 1 of the pharmacokinetic parameters of primary interest.</population>
        <group_list>
          <group group_id="O1">
            <title>60 mg/kg Azithromycin ER</title>
          </group>
          <group group_id="O2">
            <title>30 mg/kg Azithromycin IR</title>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUC Inf)</title>
          <description>AUCinf = AUClast + (Clast* divided by kel), where AUClast is calculated by Linear-Log trapezoidal method, Clast* is the predicted serum concentration at the last quantifiable time point estimated from the log-linear regression analysis and kel is the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.</description>
          <population>All subjects randomized and treated who had at least 1 of the pharmacokinetic parameters of primary interest.</population>
          <units>ng*hr/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15536.196" spread="9310.3993"/>
                    <measurement group_id="O2" value="9645.630" spread="6062.6789"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Observed Plasma Concentration (Cmax) of Azithromycin</title>
        <time_frame>Predose/0, 1, 2, 3, 4, 8, 24, 48, 72 hours post-dose</time_frame>
        <population>All subjects randomized and treated who had at least 1 of the pharmacokinetic parameters of primary interest.</population>
        <group_list>
          <group group_id="O1">
            <title>60 mg/kg Azithromycin ER</title>
          </group>
          <group group_id="O2">
            <title>30 mg/kg Azithromycin IR</title>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Plasma Concentration (Cmax) of Azithromycin</title>
          <population>All subjects randomized and treated who had at least 1 of the pharmacokinetic parameters of primary interest.</population>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="774.750" spread="477.9896"/>
                    <measurement group_id="O2" value="901.644" spread="600.6826"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of Geometric Means</param_type>
            <param_value>91.63</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>56.21</ci_lower_limit>
            <ci_upper_limit>149.38</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Reach Maximum Observed Plasma Concentration (Tmax) and Plasma Decay Half Life (t1/2) of Azithromycin</title>
        <description>Plasma decay half-life is the time measured for the plasma concentration to decrease by one-half.</description>
        <time_frame>Predose/0, 1, 2, 3, 4, 8, 24, 48, 72 hours post-dose</time_frame>
        <population>All subjects randomized and treated who had at least 1 of the pharmacokinetic parameters of primary interest.</population>
        <group_list>
          <group group_id="O1">
            <title>60 mg/kg Azithromycin ER</title>
          </group>
          <group group_id="O2">
            <title>30 mg/kg Azithromycin IR</title>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach Maximum Observed Plasma Concentration (Tmax) and Plasma Decay Half Life (t1/2) of Azithromycin</title>
          <description>Plasma decay half-life is the time measured for the plasma concentration to decrease by one-half.</description>
          <population>All subjects randomized and treated who had at least 1 of the pharmacokinetic parameters of primary interest.</population>
          <units>hr</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Tmax</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" lower_limit="2.0" upper_limit="8.0"/>
                    <measurement group_id="O2" value="2.0" lower_limit="1.0" upper_limit="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>t1/2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.303" lower_limit="15.0" upper_limit="52.2"/>
                    <measurement group_id="O2" value="28.959" lower_limit="10.4" upper_limit="49.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Concentrations of Azithromycin ER (Test) and Azithromycin IR (Reference)</title>
        <time_frame>1,2,3,4,8,24,48,72 hours postdose</time_frame>
        <population>All subjects randomized and treated who had at least 1 of the pharmacokinetic parameters of primary interest.</population>
        <group_list>
          <group group_id="O1">
            <title>60 mg/kg Azithromycin ER (Test)</title>
          </group>
          <group group_id="O2">
            <title>30 mg/kg Azithromycin IR (Reference)</title>
          </group>
        </group_list>
        <measure>
          <title>Serum Concentrations of Azithromycin ER (Test) and Azithromycin IR (Reference)</title>
          <population>All subjects randomized and treated who had at least 1 of the pharmacokinetic parameters of primary interest.</population>
          <units>ng/ml</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serum Concentration 1 hour postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.96"/>
                    <measurement group_id="O2" value="152.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Concentration 2 hour postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="293.14"/>
                    <measurement group_id="O2" value="579.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Concentration 3 hour postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="381.96"/>
                    <measurement group_id="O2" value="381.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Concentration 4 hour postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="441.79"/>
                    <measurement group_id="O2" value="267.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Concentration 8 hour postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="244.75"/>
                    <measurement group_id="O2" value="140.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Concentration 24 hour postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="142.41"/>
                    <measurement group_id="O2" value="82.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Concentration 48 hour postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.79"/>
                    <measurement group_id="O2" value="50.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Concentration 72 hour postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.03"/>
                    <measurement group_id="O2" value="30.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serum Concentration 1 hour postdose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of Geometric means (percent)</param_type>
            <param_value>65.44</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>23.56</ci_lower_limit>
            <ci_upper_limit>181.77</ci_upper_limit>
            <estimate_desc>Ratio (percent) = Test/Reference multiplied by 100</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serum Concentration 2 hours postdose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of Geometric means (percent)</param_type>
            <param_value>50.57</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>25.24</ci_lower_limit>
            <ci_upper_limit>101.30</ci_upper_limit>
            <estimate_desc>Ratio (percent) = Test/Reference multiplied by 100</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serum Concentration 3 hours postdose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of Geometric means (percent)</param_type>
            <param_value>100.07</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>57.91</ci_lower_limit>
            <ci_upper_limit>172.92</ci_upper_limit>
            <estimate_desc>Ratio (percent) = Test/Reference multiplied by 100</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serum Concentration 4 hours postdose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of Geometric means (percent)</param_type>
            <param_value>164.93</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>103.78</ci_lower_limit>
            <ci_upper_limit>262.12</ci_upper_limit>
            <estimate_desc>Ratio (percent) = Test/Reference multiplied by 100</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serum Concentration 8 hours postdose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of Geometric means (percent)</param_type>
            <param_value>174.41</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>110.07</ci_lower_limit>
            <ci_upper_limit>276.36</ci_upper_limit>
            <estimate_desc>Ratio (percent) = Test/Reference multiplied by 100</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serum Concentration 24 hours postdose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of Geometric means (percent)</param_type>
            <param_value>173.01</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>111.45</ci_lower_limit>
            <ci_upper_limit>268.55</ci_upper_limit>
            <estimate_desc>Ratio (percent) = Test/Reference multiplied by 100</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serum Concentration 48 hours postdose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of Geometric means (percent)</param_type>
            <param_value>189.35</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>129.76</ci_lower_limit>
            <ci_upper_limit>276.30</ci_upper_limit>
            <estimate_desc>Ratio (percent) = Test/Reference multiplied by 100</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serum Concentration 72 hours postdose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of Geometric means (percent)</param_type>
            <param_value>183.14</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>124.61</ci_lower_limit>
            <ci_upper_limit>269.14</ci_upper_limit>
            <estimate_desc>Ratio (percent) = Test/Reference multiplied by 100</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With a Clinical Response</title>
        <description>Clinical response was assesed between Days 7 and 10, or when subjects discontinued the study prematurely (if applicable). Response was assessed by the investigator as cure or failure. Cure = Clinical signs and symptoms related to the acute illness have resolved, or clinical improvement is such that no additional therapy is necessary. Failure = One or more of the following:
Signs and symptoms related to the acute illness have persisted or worsened and additional therapy is necessary;
New clinical signs and symptoms of acute illness have developed and additional therapy is necessary</description>
        <time_frame>Days 7,8,9 or 10</time_frame>
        <population>Any worsening of existing signs and symptoms, or new signs and symptoms, were documented as adverse events.</population>
        <group_list>
          <group group_id="O1">
            <title>60 mg/kg Azithromycin ER</title>
          </group>
          <group group_id="O2">
            <title>30 mg/kg Azithromycin IR</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Clinical Response</title>
          <description>Clinical response was assesed between Days 7 and 10, or when subjects discontinued the study prematurely (if applicable). Response was assessed by the investigator as cure or failure. Cure = Clinical signs and symptoms related to the acute illness have resolved, or clinical improvement is such that no additional therapy is necessary. Failure = One or more of the following:
Signs and symptoms related to the acute illness have persisted or worsened and additional therapy is necessary;
New clinical signs and symptoms of acute illness have developed and additional therapy is necessary</description>
          <population>Any worsening of existing signs and symptoms, or new signs and symptoms, were documented as adverse events.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Events (AEs) and Serious AEs (SAEs)</title>
        <description>All observed or volunteered AEs and SAEs regardless of treatment group or suspected causal relationship to the investigational product(s) was reported.</description>
        <time_frame>Baseline up to 28 days</time_frame>
        <population>All subjects who received at least 1 dose of study medication were included in the safety analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>60 mg/kg Azithromycin ER</title>
          </group>
          <group group_id="O2">
            <title>30 mg/kg Azithromycin IR</title>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events (AEs) and Serious AEs (SAEs)</title>
          <description>All observed or volunteered AEs and SAEs regardless of treatment group or suspected causal relationship to the investigational product(s) was reported.</description>
          <population>All subjects who received at least 1 dose of study medication were included in the safety analyses.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>60 mg/kg Azithromycin ER</title>
        </group>
        <group group_id="E2">
          <title>30 mg/kg Azithromycin IR</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (11.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Treatment failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of &lt; 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), &lt; 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.govCallCenter@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

